Selexipag vs Uptravi: Side-by-Side Comparison
Quick answer: Selexipag and Uptravi are both selective prostacyclin (ip) receptor agonist used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Selexipag | Uptravi |
|---|---|---|
| Drug class | Selective prostacyclin (IP) receptor agonist | Selective prostacyclin (IP) receptor agonist |
| ATC code | B01AC27 | B01AC27 |
| Primary indications | Pulmonary arterial hypertension | Pulmonary arterial hypertension |
| Mechanism | Selexipag and its active metabolite selectively activate the IP prostacyclin receptor causing pulmonary vasodilation and antiproliferative effects | Selective IP prostacyclin receptor agonist causing pulmonary vasodilation and inhibition of platelet aggregation |
| Common dose | 200 mcg twice daily, titrated up to 1600 mcg twice daily | 200 mcg twice daily, titrated up to 1600 mcg twice daily |
| Detail page | Selexipag details → | Uptravi details → |
How to choose between Selexipag and Uptravi
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All Selective prostacyclin (IP) receptor agonist on iMedic · Selexipag full details · Uptravi full details
Frequently asked questions
Is Selexipag better than Uptravi?
Neither is universally 'better.' They are both selective prostacyclin (ip) receptor agonist with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Selexipag to Uptravi?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Selexipag and Uptravi have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Selexipag and Uptravi available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.